MACOP-B treatment in children and adolescents with advanced diffuse large-cell non-Hodgkin's lymphoma

Victor M. Santana, Minnie Abromowitch, John T. Sandlund, Fred G. Behm, Gregory D. Ayers, Paula K. Roberson, Ching Hon Pui

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

From 1986 through 1990, 13 previously untreated pediatric patients with advanced diffuse large-cell non-Hodgkin's lymphoma (LC-NHL) were treated with a 12-week MACOP-B regimen at St Jude Children's Research Hospital. Although 12 patients (92%) achieved a complete response, and one had a partial response, the 2-year event-free survival was only 54 ± 15% (SE). Seven patients remain in continuous complete remission it a median of 40 months after therapy (range 23-57 months). Relapses occurred at sites of initial involvement in five patients it a median of 3.0 months after remission (range 1.2-8.5 months). Salvage therapy with radiation, and high-dose chemotherapy and bone marrow transplantation produced four durable second remissions. The 2-year overall survival for the entire group is 84 ± 10% (SE). The 12-week MACOP-B regimen proved feasible in an ambulatory clinic setting with only minimal toxicity. We found that MACOP-B is an effective and tolerable treatment for pediatric patients with LC-NHL but did not provide improved survival over that of a similar group of children treated in previous trials at this institution.

Original languageEnglish (US)
Pages (from-to)187-191
Number of pages5
JournalLeukemia
Volume7
Issue number2
StatePublished - Jan 1 1993

Fingerprint

Non-Hodgkin's Lymphoma
Pediatrics
Therapeutics
Salvage Therapy
Survival
Bone Marrow Transplantation
Disease-Free Survival
Radiation
Recurrence
Drug Therapy
Research
MACOP-B regimen

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Santana, V. M., Abromowitch, M., Sandlund, J. T., Behm, F. G., Ayers, G. D., Roberson, P. K., & Pui, C. H. (1993). MACOP-B treatment in children and adolescents with advanced diffuse large-cell non-Hodgkin's lymphoma. Leukemia, 7(2), 187-191.

MACOP-B treatment in children and adolescents with advanced diffuse large-cell non-Hodgkin's lymphoma. / Santana, Victor M.; Abromowitch, Minnie; Sandlund, John T.; Behm, Fred G.; Ayers, Gregory D.; Roberson, Paula K.; Pui, Ching Hon.

In: Leukemia, Vol. 7, No. 2, 01.01.1993, p. 187-191.

Research output: Contribution to journalArticle

Santana, VM, Abromowitch, M, Sandlund, JT, Behm, FG, Ayers, GD, Roberson, PK & Pui, CH 1993, 'MACOP-B treatment in children and adolescents with advanced diffuse large-cell non-Hodgkin's lymphoma', Leukemia, vol. 7, no. 2, pp. 187-191.
Santana VM, Abromowitch M, Sandlund JT, Behm FG, Ayers GD, Roberson PK et al. MACOP-B treatment in children and adolescents with advanced diffuse large-cell non-Hodgkin's lymphoma. Leukemia. 1993 Jan 1;7(2):187-191.
Santana, Victor M. ; Abromowitch, Minnie ; Sandlund, John T. ; Behm, Fred G. ; Ayers, Gregory D. ; Roberson, Paula K. ; Pui, Ching Hon. / MACOP-B treatment in children and adolescents with advanced diffuse large-cell non-Hodgkin's lymphoma. In: Leukemia. 1993 ; Vol. 7, No. 2. pp. 187-191.
@article{39608a1bed5f45a499c9bc08d5e4edd9,
title = "MACOP-B treatment in children and adolescents with advanced diffuse large-cell non-Hodgkin's lymphoma",
abstract = "From 1986 through 1990, 13 previously untreated pediatric patients with advanced diffuse large-cell non-Hodgkin's lymphoma (LC-NHL) were treated with a 12-week MACOP-B regimen at St Jude Children's Research Hospital. Although 12 patients (92{\%}) achieved a complete response, and one had a partial response, the 2-year event-free survival was only 54 ± 15{\%} (SE). Seven patients remain in continuous complete remission it a median of 40 months after therapy (range 23-57 months). Relapses occurred at sites of initial involvement in five patients it a median of 3.0 months after remission (range 1.2-8.5 months). Salvage therapy with radiation, and high-dose chemotherapy and bone marrow transplantation produced four durable second remissions. The 2-year overall survival for the entire group is 84 ± 10{\%} (SE). The 12-week MACOP-B regimen proved feasible in an ambulatory clinic setting with only minimal toxicity. We found that MACOP-B is an effective and tolerable treatment for pediatric patients with LC-NHL but did not provide improved survival over that of a similar group of children treated in previous trials at this institution.",
author = "Santana, {Victor M.} and Minnie Abromowitch and Sandlund, {John T.} and Behm, {Fred G.} and Ayers, {Gregory D.} and Roberson, {Paula K.} and Pui, {Ching Hon}",
year = "1993",
month = "1",
day = "1",
language = "English (US)",
volume = "7",
pages = "187--191",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - MACOP-B treatment in children and adolescents with advanced diffuse large-cell non-Hodgkin's lymphoma

AU - Santana, Victor M.

AU - Abromowitch, Minnie

AU - Sandlund, John T.

AU - Behm, Fred G.

AU - Ayers, Gregory D.

AU - Roberson, Paula K.

AU - Pui, Ching Hon

PY - 1993/1/1

Y1 - 1993/1/1

N2 - From 1986 through 1990, 13 previously untreated pediatric patients with advanced diffuse large-cell non-Hodgkin's lymphoma (LC-NHL) were treated with a 12-week MACOP-B regimen at St Jude Children's Research Hospital. Although 12 patients (92%) achieved a complete response, and one had a partial response, the 2-year event-free survival was only 54 ± 15% (SE). Seven patients remain in continuous complete remission it a median of 40 months after therapy (range 23-57 months). Relapses occurred at sites of initial involvement in five patients it a median of 3.0 months after remission (range 1.2-8.5 months). Salvage therapy with radiation, and high-dose chemotherapy and bone marrow transplantation produced four durable second remissions. The 2-year overall survival for the entire group is 84 ± 10% (SE). The 12-week MACOP-B regimen proved feasible in an ambulatory clinic setting with only minimal toxicity. We found that MACOP-B is an effective and tolerable treatment for pediatric patients with LC-NHL but did not provide improved survival over that of a similar group of children treated in previous trials at this institution.

AB - From 1986 through 1990, 13 previously untreated pediatric patients with advanced diffuse large-cell non-Hodgkin's lymphoma (LC-NHL) were treated with a 12-week MACOP-B regimen at St Jude Children's Research Hospital. Although 12 patients (92%) achieved a complete response, and one had a partial response, the 2-year event-free survival was only 54 ± 15% (SE). Seven patients remain in continuous complete remission it a median of 40 months after therapy (range 23-57 months). Relapses occurred at sites of initial involvement in five patients it a median of 3.0 months after remission (range 1.2-8.5 months). Salvage therapy with radiation, and high-dose chemotherapy and bone marrow transplantation produced four durable second remissions. The 2-year overall survival for the entire group is 84 ± 10% (SE). The 12-week MACOP-B regimen proved feasible in an ambulatory clinic setting with only minimal toxicity. We found that MACOP-B is an effective and tolerable treatment for pediatric patients with LC-NHL but did not provide improved survival over that of a similar group of children treated in previous trials at this institution.

UR - http://www.scopus.com/inward/record.url?scp=0027474737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027474737&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 187

EP - 191

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 2

ER -